Benzinga · Feb 26, 2026
PM
NASDAQ · PMCB
PharmaCyte Biotech, Inc.
Healthcare · Biotechnology
$0.45
Up+$0.01 (+1.79%)
Updated Sep 14, 2026, 1:15 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.93M
- P/E ratio
- -6.16
- Dividend yield
- 0.00%
- 52-week range
- $0.43 – $0.97
- Volume
- 49.04K
- Avg. volume
- 3.26M
Price performance
PMCB price history
1M range · 19 trading sessions · Daily adjusted prices
PMCB closed at $0.45 after 19 trading sessions, down 16.97% for the selected period.
- Last close
- $0.45
- Period change
- -16.97%
- Period low
- $0.44
- Period high
- $0.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.4403 | $0.468 | $0.4302 | $0.4502 | 49.04K |
| Sep 10, 2026 | $0.4809 | $0.4999 | $0.4332 | $0.4423 | 121.48K |
| Sep 9, 2026 | $0.4899 | $0.4985 | $0.4653 | $0.4753 | 66.69K |
| Sep 8, 2026 | $0.49 | $0.5198 | $0.48 | $0.489 | 230.27K |
| Sep 4, 2026 | $0.50 | $0.5009 | $0.4855 | $0.4865 | 45.37K |
| Sep 3, 2026 | $0.4896 | $0.5149 | $0.4801 | $0.4913 | 137.1K |
| Sep 2, 2026 | $0.485 | $0.4986 | $0.4702 | $0.4807 | 48.26K |
| Sep 1, 2026 | $0.49 | $0.509 | $0.4801 | $0.4881 | 55.15K |
| Aug 31, 2026 | $0.52 | $0.5298 | $0.48 | $0.5009 | 105.52K |
| Aug 28, 2026 | $0.5326 | $0.5326 | $0.5044 | $0.515 | 83.34K |
| Aug 27, 2026 | $0.5503 | $0.565 | $0.531 | $0.5402 | 57.21K |
| Aug 26, 2026 | $0.548 | $0.551 | $0.5201 | $0.5405 | 73.78K |
| Aug 25, 2026 | $0.52 | $0.5399 | $0.511 | $0.5396 | 68.4K |
| Aug 24, 2026 | $0.533 | $0.5399 | $0.52 | $0.525 | 61.99K |
| Aug 21, 2026 | $0.518 | $0.5399 | $0.5155 | $0.533 | 92.79K |
| Aug 20, 2026 | $0.5308 | $0.5324 | $0.5044 | $0.5143 | 92.82K |
| Aug 19, 2026 | $0.532 | $0.5398 | $0.5101 | $0.5324 | 54.83K |
| Aug 18, 2026 | $0.5259 | $0.54 | $0.5043 | $0.5241 | 225.95K |
| Aug 17, 2026 | $0.557 | $0.557 | $0.5221 | $0.5422 | 104.78K |
Latest PMCB news
The latest Smart Investors Daily articles mentioning PMCB.
Stock researchCompany · Overview
PMCB research
Overview
Company profile and research snapshot.
Company profile
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 8, 2021 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
defenseworld.net · Dec 5, 2025
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
Avadel Pharmaceuticals (NASDAQ: AVDL - Get Free Report) and Nuvilex (NASDAQ: PMCB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation. Risk and Volatility Avadel Pharmaceuticals has a beta of
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
